Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20544205 | 0.93 | ELANE (0.63) | ELANECCR1 | |
| SCHEMBL17023283 | 0.92 | ELANE (0.60) | ELANECCR1 | |
| SCHEMBL17023263 | 0.90 | ELANE (0.62) | ELANECCR1 | |
| SCHEMBL17023259 | 0.90 | ELANE (0.62) | ELANECCR1 | |
| SCHEMBL17023264 | 0.90 | ELANE (0.62) | ELANECCR1 | |
| SCHEMBL17035601 | 0.90 | ELANE (0.62) | ELANECCR1 | |
| SCHEMBL17023258 | 0.90 | ELANE (0.62) | ELANECCR1 | |
| SCHEMBL17035600 | 0.90 | ELANE (0.62) | ELANECCR1 | |
| SCHEMBL17023275 | 0.88 | ELANE (0.73) | ELANECCR1 | |
| SCHEMBL17023272 | 0.88 | ELANE (0.66) | ELANECCR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9221807-B2 | Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-12-29 | — | — | US | disclosed |
| US-9221807-B2 | Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-12-29 | — | — | US | disclosed |
| US-9221807-B2 | Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activity | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-12-29 | — | — | US | disclosed |
| US-20150239875-A1 | SUBSTITUTED PYRIDONES AND PYRAZINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-27 | — | — | US | disclosed |
| US-20150239875-A1 | SUBSTITUTED PYRIDONES AND PYRAZINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-27 | — | — | US | disclosed |
| US-20150239875-A1 | SUBSTITUTED PYRIDONES AND PYRAZINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239875-A1 | SUBSTITUTED PYRIDONES AND PYRAZINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITY | SERPINB1, ELANE, EPX | ELANE 2/4885CCR1 567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.